Singapore markets close in 20 minutes

GSK plc (GSK.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
1,800.76+12.26 (+0.69%)
As of 09:25AM BST. Market open.
Full screen
Previous close1,788.50
Open1,796.00
Bid1,800.50 x 0
Ask1,801.00 x 0
Day's range1,777.50 - 1,808.50
52-week range1,302.60 - 1,823.50
Volume524,471
Avg. volume7,550,683
Market cap74.64B
Beta (5Y monthly)0.27
PE ratio (TTM)16.52
EPS (TTM)1.09
Earnings date31 Jul 2024
Forward dividend & yield0.60 (3.35%)
Ex-dividend date16 May 2024
1y target estN/A
  • Benzinga

    GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims

    GSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure, accusing the pharmaceutical giant of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, once a blockbuster heartburn drug. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. In a whistleblower complaint filed on Monday, Valisure claimed GSK violated the federal False Claims Act by hid

  • Benzinga

    GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows

    Tuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterized by blood eosinophil count. Earlier this year, GSK acquired Aiolos Bio Inc., a privately held asthma drug maker, for $1 billion. Both SWIFT-1 and SWIFT-2 met their primary endpoints of a reduction in the annualized rate of clinically sign

  • Reuters

    GSK whistleblower claims drugmaker cheated US government over Zantac cancer risk

    (Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug. In a whistleblower complaint filed on Monday, Valisure said GSK violated the federal False Claims Act by hiding the risks for nearly four decades while Medicare, Medicaid and other health programs covered billions of dollars of prescriptions. The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."